Added to YB: 2025-01-07
Pitch date: 2025-01-05
MEDP [bullish]
Medpace Holdings, Inc.
+63.97%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
Market Cap
$15.4B
Pitch Price
$340.99
Price Target
453.54 (-19%)
Dividend
N/A
EV/EBITDA
26.28
P/E
38.18
EV/Sales
6.44
Sector
Life Sciences Tools and Services
Category
growth
Medpace: A Compelling Long-Term Opportunity And High-Quality Compounder!
MEDP: Leading CRO for small/mid biopharma. Strong financials: 16.19% ROIC, 67.22% gross margin, 25.87% FCF margin. Founder-CEO owns 17%+. No debt. Risks: competitive industry, client funding dependency. Growth projections: 15-20% EPS/Rev. Undervalued at current price implying 8.5% FCF growth vs. expected 17% CAGR.
Read full article (17 min)